Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8N0Z6

UPID:
TTC5_HUMAN

ALTERNATIVE NAMES:
Stress-responsive activator of p300

ALTERNATIVE UPACC:
Q8N0Z6; A8MQ18; Q96HF9

BACKGROUND:
TTC5, recognized for its regulatory functions across actin regulation, autophagy, and DNA repair, is essential for cellular homeostasis. Its interaction with cofactors like JMY and involvement in processes such as tubulin autoregulation and p53/TP53-dependent transcription highlight its critical role in maintaining cellular integrity under various stress conditions.

THERAPEUTIC SIGNIFICANCE:
The association of TTC5 with neurodevelopmental disorders underscores its potential as a target for therapeutic intervention. Exploring TTC5's functions further could lead to novel treatments for diseases characterized by developmental delays and cerebral atrophy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.